compound semaglutide fda shortage declaratory order resolved february 21 2025 The FDA has issued a warning to Compounded Semaglutide & Tirzepatide 2025: – Hims & Hers stock falls

No this compound is supplied strictly for laboratory research purposes and is not approved for personal or therapeutic use

Therefore, clinicians must balance efficacy, affordability, and patient needs when choosing therapy

Ronaldson and Davis, 2020)

Legal Considerations for Researchers For laboratories purchasing retatrutide as a chemical reference standard, the relevant compliance considerations are well-defined: the material must be labeled and sold strictly for laboratory research, must not bear instructions for human administration, must be supported by a Certificate of Analysis, and must be stored and handled under standard research-laboratory protocols